VRK1 and bladder transitional cell carcinoma: On the other hand, high VRK1 expression was linked to clinical benefits in BLCA patients receiving PDL-1 ICB therapy, resulting in increased survival durations compared to BLCA cohorts with lower VRK1 expression levels.